#United States #New York #Rosen Law Firm #securities claims #ADMA Biologics

Rosen Law Firm Investigates ADMA Biologics

The Rosen Law Firm, a prominent advocate for investor rights, has officially launched an investigation into potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). This investigation follows serious allegations concerning misleading information potentially disseminated by the company, which has raised significant concerns among current and prospective investors.

Background of the Investigation

On March 24, 2026, ADMA Biologics experienced a sharp decline in its stock price after a report from the research firm Culper Research was released. The report accused the company of engaging in practices known as "channel stuffing." Channel stuffing is a tactic where a company inflates its sales figures by shipping excessive inventory to distributors. This practice can mislead investors regarding a company's true financial health and performance. Following the publication of this critical report, ADMA Biologics' stock plummeted by 16.6%, triggering alarm bells for shareholders.

The Rosen Law Firm emphasizes the importance of investigating these claims, as it ensures that shareholders' rights are protected, and any potential wrongdoing is examined thoroughly. Investors who purchased ADMA Biologics securities during this tumultuous period could potentially be eligible for compensation under a contingency fee arrangement, meaning they may not incur any out-of-pocket costs in pursuing their claims.

Do You Qualify for the Class Action?

If you are an investor who acquired shares of ADMA Biologics, now is a critical time to consider your options. The Rosen Law Firm is currently preparing a class action lawsuit aimed at recovering losses sustained by shareholders. Investors wishing to join this class action are encouraged to visit the Rosen Law Firm's designated webpage or contact attorney Phillip Kim for further information on how to get involved.

Why Choose Rosen Law Firm?

Selecting the right legal representation is crucial when navigating securities class actions. Rosen Law Firm has established a track record of success in this arena, securing significant settlements for investors globally. Notably, the firm has been recognized as a leader in securities class action cases, having achieved notable victories against several companies. For instance, in 2019, the firm obtained over $438 million in recoveries for investors.

The Rosen Law Firm's founding partner, Laurence Rosen, has received accolades for his leadership in plaintiff cases, including being named a Titan of the Plaintiffs' Bar by Law360. Many of the firm's attorneys have garnered recognition from esteemed organizations such as Lawdragon and Super Lawyers for their contributions to investor advocacy.

For consistent updates regarding the investigation, you can follow the Rosen Law Firm on social media platforms such as LinkedIn, Twitter, and Facebook.

Conclusion

In the face of overwhelming evidence and serious allegations, shareholders of ADMA Biologics are encouraged to take immediate action. The Rosen Law Firm stands ready to assist investors in seeking justice for any potential losses incurred due to misleading information released by the company. Through the collective strength of the investor community, accountability can be pursued. To ensure your rights are protected, reach out to the Rosen Law Firm promptly for guidance and support.